Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.

Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A; Investigators of the 16-year Long-Term Follow-Up Study.

J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):907-12. doi: 10.1136/jnnp.2009.204123. Epub 2010 Jun 19.

PMID:
20562430
2.

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.

Cochrane Database Syst Rev. 2013 Jun 6;(6):CD008933. doi: 10.1002/14651858.CD008933.pub2. Review.

PMID:
23744561
3.

Interferon beta treatment for multiple sclerosis: persisting questions.

Goodkin DE.

Mult Scler. 1996 Jul;1(6):321-4. Review.

PMID:
9345408
4.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

PMID:
28440858
5.
6.

Interferon-β-1b: a review of its use in multiple sclerosis.

Plosker GL.

CNS Drugs. 2011 Jan;25(1):67-88. doi: 10.2165/11206430-000000000-00000. Review.

PMID:
21128695
7.

Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.

Arnason BG.

J Neurol. 2005 Sep;252 Suppl 3:iii28-iii33. Review.

PMID:
16170497
8.

Early treatment and dose optimisation BENEFIT and BEYOND.

Hartung HP.

J Neurol. 2005 Sep;252 Suppl 3:iii44-iii50. Review.

PMID:
16170501
9.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
10.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
11.

The importance of maintaining effective therapy in multiple sclerosis.

Durelli L, Clerico M.

J Neurol. 2005 Sep;252 Suppl 3:iii38-iii43. Review.

PMID:
16170500
12.

Does interferon beta therapy affect survival of multiple sclerosis patients?

Kułakowska A, Drozdowski W.

Neurol Neurochir Pol. 2014;48(6):436-41. doi: 10.1016/j.pjnns.2014.10.003. Epub 2014 Oct 23. Review.

PMID:
25482255
13.
14.

Interferon beta 1a for secondary progressive multiple sclerosis.

Hughes RA.

J Neurol Sci. 2003 Feb 15;206(2):199-202. Review.

PMID:
12559511
15.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
16.

Interferon-beta-1b: in newly emerging multiple sclerosis.

McKeage K.

CNS Drugs. 2008;22(9):787-92. Review.

PMID:
18698876
17.

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

Cochrane Database Syst Rev. 2014 Jul 26;(7):CD009333. doi: 10.1002/14651858.CD009333.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Nov 24;11:CD009333.

PMID:
25062935

Supplemental Content

Support Center